The Implantable Gastric Stimulator for Obesity : An Update of the European Experience in the LOSS (Laparoscopic Obesity Stimulation Survey) Study.

Karl Miller, Elizabeth Hoeller, Franz Aigner
{"title":"The Implantable Gastric Stimulator for Obesity : An Update of the European Experience in the LOSS (Laparoscopic Obesity Stimulation Survey) Study.","authors":"Karl Miller,&nbsp;Elizabeth Hoeller,&nbsp;Franz Aigner","doi":"10.2165/00024677-200605010-00006","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of a gastric stimulation procedure for the treatment of morbid obesity.</p><p><strong>Methods: </strong>All implantable gastric stimulator systems were implanted in a laparoscopic procedure. We focused on the results of the LOSS (Laparoscopic Obesity Stimulation Survey) study, which was a multicenter European survey of 16 hospitals. To date, 91 patients have undergone implantable gastric stimulator implantation in the LOSS study.</p><p><strong>Results: </strong>The patient population was comprised of 62 (68%) women and 29 (32%) men. The mean age was 41 years, mean weight was 116kg, and mean body mass index was 41 kg/m(2). All surgical procedures were successfully completed. There were no deaths, and no severe peri- or postoperative complications. The mean excess weight loss (EWL) was 20% at 12 months after surgery and about 25% at 2 years after implantation. Baroscreen-selected patients achieved a 31.4% EWL, which was significantly different to the EWL of those patients who were not selected by this screening (15% EWL) [p < 0.01].</p><p><strong>Conclusion: </strong>Gastric pacing is a promising, minimally invasive, safe, and effective surgical method that results in very little impairment of the patient. Patient selection for gastric stimulation therapy seems to be an important determinant of treatment outcome.</p>","PeriodicalId":23310,"journal":{"name":"Treatments in Endocrinology","volume":"5 1","pages":"53-8"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00024677-200605010-00006","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Treatments in Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00024677-200605010-00006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

Objective: To evaluate the efficacy of a gastric stimulation procedure for the treatment of morbid obesity.

Methods: All implantable gastric stimulator systems were implanted in a laparoscopic procedure. We focused on the results of the LOSS (Laparoscopic Obesity Stimulation Survey) study, which was a multicenter European survey of 16 hospitals. To date, 91 patients have undergone implantable gastric stimulator implantation in the LOSS study.

Results: The patient population was comprised of 62 (68%) women and 29 (32%) men. The mean age was 41 years, mean weight was 116kg, and mean body mass index was 41 kg/m(2). All surgical procedures were successfully completed. There were no deaths, and no severe peri- or postoperative complications. The mean excess weight loss (EWL) was 20% at 12 months after surgery and about 25% at 2 years after implantation. Baroscreen-selected patients achieved a 31.4% EWL, which was significantly different to the EWL of those patients who were not selected by this screening (15% EWL) [p < 0.01].

Conclusion: Gastric pacing is a promising, minimally invasive, safe, and effective surgical method that results in very little impairment of the patient. Patient selection for gastric stimulation therapy seems to be an important determinant of treatment outcome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于肥胖的植入式胃刺激器:欧洲腹腔镜肥胖刺激调查研究经验的更新。
目的:评价胃刺激术治疗病态肥胖的疗效。方法:在腹腔镜手术中植入所有植入式胃刺激器系统。我们关注的是LOSS(腹腔镜肥胖刺激调查)研究的结果,这是一项欧洲16家医院的多中心调查。迄今为止,在LOSS研究中已有91例患者接受了植入式胃刺激器植入。结果:患者中女性62例(68%),男性29例(32%)。平均年龄41岁,平均体重116kg,平均体重指数41 kg/m(2)。所有手术均顺利完成。无死亡,无严重的围手术期或术后并发症。术后12个月平均体重减轻20%,术后2年平均体重减轻25%。经气压筛检的患者EWL为31.4%,与未经气压筛检的患者EWL(15%)有显著差异[p < 0.01]。结论:胃起搏是一种微创、安全、有效的手术方法,对患者的损害很小。患者选择胃刺激治疗似乎是治疗结果的重要决定因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Oxyntomodulin Prenatal treatment of congenital adrenal hyperplasia : do we have enough evidence? The role of melanocyte-stimulating hormone in insulin resistance and type 2 diabetes mellitus. The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options. Thiazolidinediones : beyond glycemic control.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1